ReviewOncoimmunology2025

Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy.

Kengo Tanigawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.